Netazepide
Netazepide has been studied in 1 paper since 2025: 1 trial in people. The newest paper, Nov 9, 2025: “Randomized controlled trial of an oral gastrin receptor antagonist for the treatment of postmenopausal osteoporosis”.
See all 1 papers on netazepide
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“We found that gastrin increased by 90% in response to GRA as early as 7 d (p-value for treatment: .0008)”
None of its findings points the other way.
- 1 lab in 1 country
- 6 of 6 findings with company ties
- Human trial1
Studies in people
1 study gave netazepide to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on CTX up: Increases gastrin+90% down: Decreases pepsinogen I-15% | Randomized trial90 d | 99 peoplewomenmean age of 60 yrPostmenopausal women | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, Nov 9, 2025 |
What did studies of netazepide find?
3Studies of netazepide measured 3 outcomes: pepsinogen I, gastrin and CTX.
Pepsinogen I
downin humans1−15%
1 study
Pepsinogen I
downin humans1−15%
Netazepide decreases pepsinogen I in humans (-15%).
Human trial90 dfemalesn = 99
Netazepide decreases pepsinogen I in humans (-15% (p = .0002)).
Human trial100 mg daily90 dfemalesn = 99
Gastrin
upin humans1+90%
1 study
Gastrin
upin humans1+90%
Netazepide increases gastrin in humans (+90%).
Human trial90 dfemalesn = 99
Netazepide increases gastrin in humans (+90% (p = .0008)).
Human trial100 mg daily90 dfemalesn = 99
CTX
no changein humans1
1 study
CTX
no changein humans1
Netazepide showed no clear effect on CTX in humans.
Human trial90 dfemalesn = 99
Netazepide showed no clear effect on CTX in humans (no significant change).
Human trial100 mg daily90 dfemalesn = 99